Edwards lifts 2026 sales growth outlook to 10%-11% while reaffirming $2.95-$3.05 EPS
Seeking Alpha ·
Earnings Call Insights: Edwards Lifesciences (EW) Q2 2026 CEO Bernard Zovighian said the quarter came in ahead of plan: "We delivered stronger-than-expected second quarter sales growth of 12.5%." He tied performance to breadth across therapies and geographies, adding, "our results increasingly reflect
DYAX Investor Sentiment
Bullish (Long) 49% · Bearish (Short) 51%
309 participants
Related News
- Newmont outlines Lihir nearshore barrier unlocking over 5 million ounces beginning in 2028, while holding 2026 guidance
- Boyd raises 2026 online EBITDAR outlook to $35M-$40M while targeting $150M quarterly buybacks
- AtriCure targets $602M-$610M 2026 revenue while raising adjusted EBITDA outlook to $85M-$89M
- 47 Analysts Cover Apple. Their Average Price Target Is Now Below the Stock Price, One Week Before Earnings.
- Columbia Banking System anticipates NIM beyond 4% in 2026 while planning $150M-$200M of Q3 buybacks
- 2 Hidden Businesses to Watch as AI Keeps Heating Up
